NCT07363824

Brief Summary

This study aims to see if the amount of iron in tears is linked to how severe dry eye disease is. We hope this can lead to a new way to help diagnose and understand dry eye. This is an observational study. We will compare tear samples from people with dry eye to samples from people with healthy eyes. We will measure the iron content in the tears and see if it correlates with standard dry eye test results and symptom scores.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
52

participants targeted

Target at P25-P50 for all trials

Timeline
36mo left

Started Feb 2026

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress8%
Feb 2026May 2029

First Submitted

Initial submission to the registry

January 5, 2026

Completed
18 days until next milestone

First Posted

Study publicly available on registry

January 23, 2026

Completed
14 days until next milestone

Study Start

First participant enrolled

February 6, 2026

Completed
3.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2029

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2029

Last Updated

February 10, 2026

Status Verified

January 1, 2026

Enrollment Period

3.2 years

First QC Date

January 5, 2026

Last Update Submit

February 6, 2026

Conditions

Keywords

DEDiron

Outcome Measures

Primary Outcomes (1)

  • Correlation between tear fluid iron concentration and dry eye symptom severity

    The strength of association between the concentration of iron (in μg/mL) in tear fluid collected via Schirmer strips and the total score on the Ocular Surface Disease Index (OSDI) questionnaire.

    baseline

Secondary Outcomes (3)

  • Correlation between tear fluid iron concentration and tear film stability

    baseline

  • Correlation between tear fluid iron concentration and tear secretion volume

    baseline

  • Correlation between tear fluid iron concentration and corneal epithelial damage

    baseline

Study Arms (2)

CON

Procedure: Diagnostic tear fluid collection and ocular surface evaluation

DED

Procedure: Diagnostic tear fluid collection and ocular surface evaluation

Interventions

This is an observational study; no therapeutic intervention is administered. All participants undergo a single, standardized study visit that includes: Tear Fluid Collection: Tear samples are collected using sterile Schirmer test strips (without anesthesia) placed in the lower conjunctival sac for 5 minutes. Comprehensive Ocular Surface Evaluation: Symptom Assessment: Completion of the Ocular Surface Disease Index (OSDI) questionnaire. Clinical Tests: Measurement of fluorescein tear film breakup time (FBUT), corneal fluorescein staining (CFS) scoring, and Schirmer I test. The collected tear samples are subsequently analyzed for iron concentration. All procedures are diagnostic and evaluative in nature.

CONDED

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Based on your study protocol, here is the description for the "Study Population Description" field: This single-center, cross-sectional study will recruit participants from the patient population and staff/community at the Ophthalmology Department of Shanghai Changzheng Hospital. The Dry Eye Disease (DED) group will consist of consecutive patients presenting to the clinic who are diagnosed with DED according to the 2024 Chinese Expert Consensus criteria. The healthy control group will be recruited through hospital staff volunteers and community advertisements. All participants will be enrolled during the specified study period from the single site.

You may qualify if:

  • Aged between 18 and 70 years, inclusive.
  • Willing and able to provide written informed consent.

You may not qualify if:

  • History or clinical suspicion of significant systemic conditions: hematologic diseases, severe systemic infections, malignancies (treated or untreated), or chronic hepatic/renal insufficiency.
  • Use of artificial tears or any topical eye drops within 2 hours prior to examination.
  • Active ocular allergy, infection, or severe blepharitis within the past 1 month.
  • Systemic or topical use of antibiotics, corticosteroids, NSAIDs, or immunosuppressants within the past 1 month.
  • History of contact lens wear within the past 1 month.
  • History of blood transfusion, ocular surgery, or significant ocular trauma within the past 6 months.
  • Women who are pregnant, breastfeeding, or postmenopausal women undergoing hormone replacement therapy.
  • Known hypersensitivity to fluorescein sodium.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Changzheng Hospital

Shanghai, China

RECRUITING

MeSH Terms

Conditions

Dry Eye Syndromes

Condition Hierarchy (Ancestors)

Lacrimal Apparatus DiseasesEye Diseases

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chief of Ophthalmology

Study Record Dates

First Submitted

January 5, 2026

First Posted

January 23, 2026

Study Start

February 6, 2026

Primary Completion (Estimated)

May 1, 2029

Study Completion (Estimated)

May 1, 2029

Last Updated

February 10, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share

Locations